Tau‐targeted treatment strategies in Alzheimer's disease
Open accessThe DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
With populations ageing worldwide, the need for treating and preventing diseases associated with high age is pertinent. Alzheimer's disease (AD) is reaching epidemic proportions, yet the currently available therapies are limited to a symptomatic relief, without halting the degenerative process that characterizes the AD brain. As in AD cholinergic neurons are lost at high numbers, the initial strategies were limited to the development of acetylcholinesterase inhibitors, and more recently the NMDA receptor antagonist memantine, in counteracting excitotoxicity. With the identification of the protein tau in intracellular neurofibrillary tangles and of the peptide amyloid‐β (Aβ) in extracellular amyloid plaques in the AD brain, and a better understanding of their role in disease, newer strategies are emerging, which aim at either preventing their formation and deposition or at accelerating their clearance. Interestingly, what is well established to combat viral diseases in peripheral organs – vaccination – seems to work for the brain as well. Accordingly, immunization strategies targeting Aβ show efficacy in mice and to some degree also in humans. Even more surprising is the finding in mice that immunization strategies targeting tau, a protein that forms aggregates in nerve cells, ameliorates the tau‐associated pathology. We are reviewing the literature and discuss what can be expected regarding the translation into clinical practice and how the findings can be extended to other neurodegenerative diseases with protein aggregation in brain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., et al. (2006) · Science · doi:10.1126/science.1134108 · Cited by 6,576 · cited 2×
“In this subset, the transcription and splicing factor TDP-43 (TAR DNA-binding protein 43) has been identified as the aggregating protein, and consequently, this form of FTLD has been named FTLDTDP (Neumann et al., 2006).”
BackgroundGrundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498 · cited 4×
“In FTDP-17, a subset of FTLD, pathogenic mutations have been identified in the MAPT gene encoding tau (Hutton et al., 1998; Poorkaj et al., 1998; Spillantini et al., 1998).”
BackgroundInfluentialImmunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
A protein factor essential for microtubule assembly
Weingarten, M. D., Lockwood, A. H., Hwo, S. Y., & Kirschner, M. W. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.5.1858 · Cited by 3,089
Lee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480 · cited 1×
“They are generated by the presence or absence of two aminoterminal inserts (0N, 1N, 2N) and the presence or absence of the second repeat region, resulting in either three- (3R) or four-repeat (4R) isoforms (Lee et al., 2001).”
BackgroundStaging of alzheimer's disease-related neurofibrillary changes
Braak, H., & Braak, E. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00021-6 · Cited by 2,357
Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336
Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174 · cited 1×
“In FTLD, tau pathology is found in the absence of overt Ab formation (Ballatore et al., 2007).”
BackgroundBard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012 · cited 1×
“Subsequently, an Ab-directed passive vaccination approach was found to be similarly effective (Bard et al., 2000).”
MethodReducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892 · cited 2×
“In light of the finding that Ab pathology depends on the presence of tau (Roberson et al., 2007; Ittner et al., 2010), and that many tauopathies are characterized by tau pathology in the absence of Ab deposition, it makes absolute sense to pursue a tau-targeted treatment strategy, either alone or for AD in combination…”
BackgroundDendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models
Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B. C., Christie, M. J., Napier, I. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.036 · Cited by 1,821
Self-citationTransmission and spreading of tauopathy in transgenic mouse brain
Clavaguera, F., Bolmont, T., Crowther, R. A., Abramowski, D., Frank, S., Probst, A., Fraser, G., Stalder, A. K., Beibel, M., Staufenbiel, M., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1901 · Cited by 1,803
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611 · cited 2×
“…immunization strategies in AD There is a cross-talk between Ab and tau as shown by the finding that in tau transgenic mouse models, NFTs can be induced either by intracranial injection of Ab (Gotz et al., 2001b) or by breeding tau mutant mice with mice that produce Ab deposits (Lewis et al., 2001).”
BackgroundExtensive Involvement of Autophagy in Alzheimer Disease: An Immuno-Electron Microscopy Study
Nixon, R. A., Wegiel, J., Kumar, A., Yu, W. H., Peterhoff, C., Cataldo, A., & Cuervo, A. M. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/64.2.113 · Cited by 1,588
Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils
Götz, J., Chen, F., van Dorpe, J., & Nitsch, R. M. (2001) · Science · doi:10.1126/science.1062097 · Cited by 1,526 · cited 3×
“…APPtg/tautg mice that show a particularly early mortality: increased levels of tau in FTD mutant tau transgenic mice (tautg, such as the pR5 mice) (Gotz et al., 2001b) result in the accumulation of tau in the neuronal soma and dendrites, and consequently an increase in postsynaptic Fyn levels.”
BackgroundMethodHolmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416 · cited 1×
“Whether these approaches will lead to the anticipated outcome remains to be seen as for those human cases from the first trial that were followed up no cognitive benefits of the amyloid clearance could be detected (Holmes et al., 2008).”
BackgroundTau is a candidate gene for chromosome 17 frontotemporal dementia
Poorkaj, P., Bird, T. D., Wijsman, E., Nemens, E., Garruto, R. M., Anderson, L., Andreadis, A., Wiederholt, W. C., Raskind, M., & Schellenberg, G. D. (1998) · Annals of Neurology · doi:10.1002/ana.410430617 · Cited by 1,374 · cited 2×
“In FTDP-17, a subset of FTLD, pathogenic mutations have been identified in the MAPT gene encoding tau (Hutton et al., 1998; Poorkaj et al., 1998; Spillantini et al., 1998).”
BackgroundSubacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073623.84147.a8 · Cited by 1,356 · cited 1×
“Encouraged by the efficacy in mice, a clinical trial was launched with AN-1792 containing pre-aggregated synthetic Ab42 and the adjuvant QS-21 (Orgogozo et al., 2003).”
MethodDeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298 · cited 1×
“(ii) Peripheral sink: This mechanism does not need a penetration of the CNS by the antibodies; instead, it suggests that the presence of circulating antibodies creates a ‘peripheral sink’, which alters the equilibrium across the BBB for Ab, favouring an efflux (DeMattos et al., 2001).”
BackgroundPropagation of Tau Misfolding from the Outside to the Inside of a Cell
Frost, B., Jacks, R. L., & Diamond, M. I. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808759200 · Cited by 1,252 · cited 1×
“That tau can be released from and be taken up by cells has been shown in multiple experimental systems (Frost et al., 2009; Kim et al., 2010).”
BackgroundDonepezil for dementia due to Alzheimer’s disease.
Birks, J. S., & Harvey, R. J. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001190.pub3 · Cited by 1,200
McShane, R., Areosa Sastre, A., & Minakaran, N. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub5 · Cited by 1,155
Goedert, M., Wischik, C. M., Crowther, R. A., Walker, J. E., & Klug, A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.11.4051 · Cited by 1,134 · cited 1×
“The focus shifted radically when tau was identified in a highly phosphorylated form as the filamentous core of the neurofibrillary tangles (Grundke-Iqbal et al., 1986; Goedert et al., 1988).”
BackgroundMorris, M., Maeda, S., Vossel, K., & Mucke, L. (2011) · Neuron · doi:10.1016/j.neuron.2011.04.009 · Cited by 899 · cited 1×
“At present, the tau-targeted therapies that are in clinical trials target tau phosphorylation by GSK3 (lithium), microtubule stability and aggregation (Morris et al., 2011).”
BackgroundOddo, S., Billings, L., Kesslak, J. P., Cribbs, D. H., & LaFerla, F. M. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.003 · Cited by 780
Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses
Bertram, L., & Tanzi, R. E. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2494 · Cited by 747 · cited 2×
“In three genes, autosomal-dominant mutations have been iden- tified, in APP itself, as well as in presenilin 1 (PSEN1) and 2 (PSEN2) that both encode a component of the enzyme complex that is required to generate Ab (Bertram and Tanzi, 2008).”
BackgroundCHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation
Petrucelli, L. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh083 · Cited by 723
Noble, W., Planel, E., Zehr, C., Olm, V., Meyerson, J., Suleman, F., Gaynor, K., Wang, L., LaFrancois, J., Feinstein, B., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500466102 · Cited by 709 · cited 1×
“These include the GSK3 inhibitor lithium chloride that reduced levels of insoluble tau, hyperphosphorylated tau and behavioural impairment in various tau transgenic mouse models (Perez et al., 2003; Noble et al., 2005; Engel et al., 2006; Caccamo et al., 2007).”
BackgroundTau protein pathology in neurodegenerative diseases
Spillantini, M. G., & Goedert, M. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01337-x · Cited by 683
Animal models of Alzheimer's disease and frontotemporal dementia
Götz, J., & Ittner, L. M. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2420 · Cited by 676 · cited 1×
“The familial forms of AD and FTLD allowed for expression of the mutant genes in transgenic mice and hence reproducing Ab plaque and NFT formation in vivo (Gotz, 2001; Gotz and Ittner, 2008; Ashe and Zahs, 2010).”
BackgroundSelf-citationDickey, C. A., Kamal, A., Lundgren, K., Klosak, N., Bailey, R. M., Dunmore, J., Ash, P., Shoraka, S., Zlatkovic, J., Eckman, C. B., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29715 · Cited by 642 · cited 4×
“Large immunophilins such as FKBP51 and FKBP52 are also co-chaperones of HSP90–tau complexes (Salminen et al., 2011).”
MethodInfluentialBallard, C., Hanney, M. L., Theodoulou, M., Douglas, S., McShane, R., Kossakowski, K., Gill, R., Juszczak, E., Yu, L.-M., & Jacoby, R. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70295-3 · Cited by 567
Ishihara, T., Hong, M., Zhang, B., Nakagawa, Y., Lee, M. K., Trojanowski, J. Q., & Lee, V. M.-Y. (1999) · Neuron · doi:10.1016/s0896-6273(00)81127-7 · Cited by 564 · cited 1×
“In tau transgenic mice with axonopathy, amyotrophy and, consequently, a motor phenotype, a reduction in microtubule density and fast axonal transport was found (Ishihara et al., 1999; 2001).”
BackgroundEffects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease
Masliah, E., Rockenstein, E., Adame, A., Alford, M., Crews, L., Hashimoto, M., Seubert, P., Lee, M., Goldstein, J., Chilcote, T., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.05.010 · Cited by 542
Rivastigmine for Alzheimer’s disease.
Birks, J. S., Chong, L.-Y., & Grimley Evans, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001191.pub4 · Cited by 534
Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms
Andorfer, C., Acker, C. M., Kress, Y., Hof, P. R., Duff, K., & Davies, P. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4637-04.2005 · Cited by 511 · cited 2×
“Similar results were obtained by immunizing mice that express all six human tau isoforms on an MAPT-/- background, the htau model (Andorfer et al., 2005), together with M146L mutant PS1 (Boutajangout et al.”
ResultAsuni, A. A., Boutajangout, A., Quartermain, D., & Sigurdsson, E. M. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2361-07.2007 · Cited by 506 · cited 8×
“, 2006), subsequent active immunization approaches using a tau phospho-peptide showed efficacy by preventing a pathology in tau transgenic models, in the absence of obvious side effects (Asuni et al., 2007; Boimel et al., 2010; Boutajangout et al., 2010).”
BackgroundMethodInfluentialTau filament formation in transgenic mice expressing P301L tau
Götz, J., Chen, F., Barmettler, R., & Nitsch, R. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006531200 · Cited by 495 · cited 3×
“…APPtg/tautg mice that show a particularly early mortality: increased levels of tau in FTD mutant tau transgenic mice (tautg, such as the pR5 mice) (Gotz et al., 2001b) result in the accumulation of tau in the neuronal soma and dendrites, and consequently an increase in postsynaptic Fyn levels.”
BackgroundMethodSelf-citationProteasome inhibition by paired helical filament‐tau in brains of patients with Alzheimer's disease
Keck, S., Nitsch, R., Grune, T., & Ullrich, O. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01642.x · Cited by 483
Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies
Brunden, K. R., Trojanowski, J. Q., & Lee, V. M.-Y. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2959 · Cited by 440 · cited 4×
“Several approaches to therapeutically target tau pathology have been pursued in animal models in recent years (Brunden et al., 2009) (Figure 3).”
BackgroundInfluentialZhang, B., Maiti, A., Shively, S., Lakhani, F., McDonald-Jones, G., Bruce, J., Lee, E. B., Xie, S. X., Joyce, S., Li, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406361102 · Cited by 413 · cited 1×
“Because paclitaxel does not cross the blood–brain barrier (BBB) easily, one would conclude that it is the uptake at peripheral neuromuscular junctions and the subsequent retrograde transport to spinal motor neurons that caused the observed improvements (Zhang et al., 2005).”
BackgroundProbing the biology of Alzheimer’s disease in mice
Ashe, K. H., & Zahs, K. R. (2010) · Neuron · doi:10.1016/j.neuron.2010.04.031 · Cited by 413
Management of agitation and aggression associated with Alzheimer disease
Ballard, C. G., Gauthier, S., Cummings, J. L., Brodaty, H., Grossberg, G. T., Robert, P., & Lyketsos, C. G. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.39 · Cited by 404 · cited 2×
“Finally, anticonvulsants are used off licence as there is preliminary evidence from small randomized controlled trials that this might be an effective treatment of agitation or aggression in AD (C.G. Ballard et al., 2009).”
BackgroundAnalysis of microtubule-associated protein tau glycation in paired helical filaments.
Ledesma, M. D., Bonay, P., Colaço, C., & Avila, J. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31849-5 · Cited by 333 · cited 1×
“This type of modification renders tau resistant to proteolysis, thus assisting in its aggregation (Ledesma et al., 1994).”
BackgroundProteasomal degradation of tau protein
David, D. C., Layfield, R., Serpell, L., Narain, Y., Goedert, M., & Spillantini, M. G. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01137.x · Cited by 327 · cited 1×
“Natively unfolded tau can be directly processed by the 20S proteasome without a requirement for ubiquitylation (David et al., 2002).”
BackgroundNeuroleptic drugs in dementia: benefits and harm
Ballard, C., & Howard, R. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1926 · Cited by 308 · cited 1×
“…treated with antipsychotic drugs that are used to combat agitation, aggression and psychosis, but the benefits are moderate, with severe side effects such as sedation and Parkin- British Journal of Pharmacology (2012) 165 1246–1259 1247 sonism (Ballard and Howard, 2006; C. Ballard et al., 2009).”
BackgroundBoutajangout, A., Ingadottir, J., Davies, P., & Sigurdsson, E. M. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07337.x · Cited by 306 · cited 1×
“Finally, a passive immunization approach has been applied by two research teams: The first study immunized 2 to 3 month-old JNPL3 mice weekly with either PHF1 antibodies (250 mg per 125 mL) or pooled mouse IgG for a total of 13 injections (Boutajangout et al., 2011).”
Methodvan Eersel, J., Ke, Y. D., Liu, X., Delerue, F., Kril, J. J., Götz, J., & Ittner, L. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009038107 · Cited by 284
Self-citationLopez, O. L., Becker, J. T., Wahed, A. S., Saxton, J., Sweet, R. A., Wolk, D. A., Klunk, W., & DeKosky, S. T. (2009) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.158964 · Cited by 266 · cited 1×
“There also seem to be additive benefits of combining a cholinesterase inhibitor and memantine (Lopez et al., 2009).”
BackgroundWilcock, G. K., Ballard, C. G., Cooper, J. A., & Loft, H. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0302 · Cited by 253
Lemere, C. A., Beierschmitt, A., Iglesias, M., Spooner, E. T., Bloom, J. K., Leverone, J. F., Zheng, J. B., Seabrook, T. J., Louard, D., Li, D., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63296-8 · Cited by 230
Immunotherapy for Alzheimer’s disease: Key Symposium: Immunotherapy for Alzheimer’s disease
Morgan, D. (2011) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02315.x · Cited by 225
Engel, T., Goñi‐Oliver, P., Lucas, J. J., Avila, J., & Hernández, F. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04139.x · Cited by 223 · cited 1×
“These include the GSK3 inhibitor lithium chloride that reduced levels of insoluble tau, hyperphosphorylated tau and behavioural impairment in various tau transgenic mouse models (Perez et al., 2003; Noble et al., 2005; Engel et al., 2006; Caccamo et al., 2007).”
BackgroundDelayed embryonic lethality in mice lacking protein phosphatase 2A catalytic subunit Cα
Götz, J., Probst, A., Ehler, E., Hemmings, B., & Kues, W. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.21.12370 · Cited by 220 · cited 1×
“Further interactions of the MBR domain include the microfilaments (actin), organelles such as mitochondria or the tau phosphatase PP2A, an enzyme whose physiological functions we have studied in detail (Gotz et al., 1998; Kins et al., 2001; 2003).”
BackgroundSelf-citationGauthier, S., Loft, H., & Cummings, J. (2008) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1949 · Cited by 220
Kins, S., Crameri, A., Evans, D. R. H., Hemmings, B. A., Nitsch, R. M., & Götz, J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102621200 · Cited by 203
Self-citationTau Phosphorylation Sites Work in Concert to Promote Neurotoxicity In Vivo
Steinhilb, M. L., Dias-Santagata, D., Fulga, T. A., Felch, D. L., & Feany, M. B. (2007) · Molecular Biology of the Cell · doi:10.1091/mbc.e07-04-0327 · Cited by 187 · cited 1×
“…is believed to help identify kinases and phosphatases involved in its hyperphosphorylation and dephosphorylation respectively (Ferrari et al., 2003; British Journal of Pharmacology (2012) 165 1246–1259 1251 Hoerndli et al., 2004; Pennanen and Gotz, 2005; Steinhilb et al., 2007) (Figure 3).”
BackgroundTauopathy-like Abnormalities and Neurologic Deficits in Mice Immunized With Neuronal Tau Protein
Rosenmann, H., Grigoriadis, N., Karussis, D., Boimel, M., Touloumi, O., Ovadia, H., & Abramsky, O. (2006) · Archives of Neurology · doi:10.1001/archneur.63.10.1459 · Cited by 178 · cited 3×
“While the vaccination with full-length tau caused encephalitis (Rosenmann et al., 2006), subsequent active immunization approaches using a tau phospho-peptide showed efficacy by preventing a pathology in tau transgenic models, in the absence of obvious side effects (Asuni et al.”
BackgroundMethodInfluentialEfficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice
Boimel, M., Grigoriadis, N., Lourbopoulos, A., Haber, E., Abramsky, O., & Rosenmann, H. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.05.010 · Cited by 174 · cited 9×
“, 2007), another study showed antibodies in brain vessels, but not neurons or brain parenchyma (Boimel et al., 2010).”
BackgroundInfluentialDickey, C. A., Dunmore, J., Lu, B., Wang, J., Lee, W. C., Kamal, A., Burrows, F., Eckman, C., Hutton, M., & Petrucelli, L. (2006) · The FASEB Journal · doi:10.1096/fj.05-5343fje · Cited by 160 · cited 4×
“Large immunophilins such as FKBP51 and FKBP52 are also co-chaperones of HSP90–tau complexes (Salminen et al., 2011).”
MethodInfluentialKins, S., Kurosinski, P., Nitsch, R. M., & Götz, J. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63444-x · Cited by 155 · cited 1×
“Further interactions of the MBR domain include the microfilaments (actin), organelles such as mitochondria or the tau phosphatase PP2A, an enzyme whose physiological functions we have studied in detail (Gotz et al., 1998; Kins et al., 2001; 2003).”
BackgroundSelf-citationBi, M., Ittner, A., Ke, Y. D., Götz, J., & Ittner, L. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026860 · Cited by 153 · cited 1×
“In Bi et al. (2011), we found that immunization of P301L tau mutant pR5 mice with the PHF1 peptide slowed the progression of tau pathology, by decreasing tau phosphorylation, reducing NFT numbers and – in aged mice – causing astrocyte activation.”
BackgroundSelf-citationA role for FKBP52 in tau protein function
Chambraud, B., Sardin, E., Giustiniani, J., Dounane, O., Schumacher, M., Goedert, M., & Baulieu, E.-E. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914957107 · Cited by 140
Kuhla, B., Haase, C., Flach, K., Lüth, H.-J., Arendt, T., & Münch, G. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m609521200 · Cited by 119 · cited 1×
“Another facet of tau aggregation is that in the course of disease tau becomes cross-linked by reactive carbonyl compounds, leading to the formation of advanced glycation end-products (AGEs) (Kuhla et al., 2007).”
Background
Cited by
Roles of tau protein in health and disease
Guo, T., Noble, W., & Hanger, D. P. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1707-9 · Cited by 1,003
Alzheimer disease therapy—moving from amyloid-β to tau
Giacobini, E., & Gold, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.223 · Cited by 471
Role of tau protein in Alzheimer’s disease: The prime pathological player
Muralidar, S., Ambi, S. V., Sekaran, S., Thirumalai, D., & Palaniappan, B. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.07.327 · Cited by 278
Soluble forms of tau are toxic in Alzheimer's disease
Kopeikina, K., Hyman, B., & Spires-Jones, T. (2012) · Translational Neuroscience · doi:10.2478/s13380-012-0032-y · Cited by 232
“Inhibiting or reversing tau aggregation has been one of the most avidly pursued and more promising avenues of tau targeted therapies to date [1, 16].”
BackgroundInfluentialGoyal, D., Shuaib, S., Mann, S., & Goyal, B. (2017) · ACS Combinatorial Science · doi:10.1021/acscombsci.6b00116 · Cited by 227
Metadata
- Authors
- Götz, J., Ittner, A., & Ittner, L. M.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2012-02-10
- Volume
- 165
- Issue
- 5
- Pages
- 1246-1259
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1530520327
- Cited by
- 129
- References
- 65
- FWCI
- 6.93
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.